Question of the Day

Question of the Day – Friday January 20, 2017

Question: Individuals requiring chronic transfusion therapy are often treated with the iron chelator deferoxamine in order to address transfusion-induced hemochromatosis and associated complications. Which toxicities have been associated with the use of deferoxamine?

View full post for answer.

Question of the Day – Thursday January 19, 2017

Question: MEK inhibitors (inhibit the mitogen- activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) kinase) are a relatively new class of chemotherapeutic agents used in the treatment of a variety of metastatic cancers. These agents have been associated with the development of ocular toxicity. What is the nature of this toxicity?

View full post for answer.